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Diabetic Nephropathy:  
From Bench to Bedside
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A b s t r A c t
Diabetes mellitus together with arterial hypertension are the most common causes of 
chronic kidney disease. Notably, diabetic kidney disease remains a major and inde-
pendent risk for premature mortality. Therefore, continuous and accurate control of 
risk factors for the development of diabetic nephropathy is mandatory. Measurement 
of serum creatinine levels and calculation of estimated glomerular filtration rate ac-
cording to CKD-EPI equation must be performed annually. Also, measurement of 
urine albumin and calculation of the urine albumin to creatinine ratio rate is recom-
mended to be performed annually, too, as ratio >30 mg/g creatinine is considered 
to be a continuous risk factor for cardiovascular disease. Equally important is good 
glycemic control, as determined by glycated hemoglobin levels of <7%, as well as 
control of hypertension, often with more than three anti-hypertensive drugs needed 
to achieve this goal. Inhibition of the renin-angiotensin-aldosterone system is not only 
effective in managing hypertension, but seems to reduce albuminuria levels among 
patients with diabetic nephropathy. Other antihypertensive drugs which decrease al-
buminuria levels are the newer dihydropyridines calcium blockers manidipine and 
the latest b-blockers (carvedilol). Dyslipidemia parameters should be improved, too, 
especially the serum LDL-cholesterol levels <100 mg/dl. Vitamin D analogues have 
been shown to decrease albuminuria if glomerular filtration rate <60 ml/min/1.73 cm2. 
Besides, sodium glucose co-transporter 2 inhibitors, which produce glucosuria seem 
to possess nephroprotective properties among type 2 diabetic patients. In particular, 
the EMPAREG study has documented that empagliflozin reduces the relative risk of 
serum creatinine doubling by 44%, while the relative risk of introducing hemoperfu-
sion has been decreased by 55% within four years. It seems likely that atrasentan, 
a selective antagonist of the receptor of endothelin A also reduces albuminuria by 
approximately 35%. Moreover, the significance of substances with anti-inflammatory 
properties, such as oxidase inhibitors, pentoxyfilline, and N-acetyl-cysteine remains 
to be elucidated. It is noteworthy that weight loss together with dietary consultation, 
not only are implicated in better glycemic control and dyslipidemia management, but 
also in improving diabetic nephropathy per se.
I n t r o d u c t I o n
Diabetic kidney disease or diabetic nephropathy is the most common cause of 
chronic kidney disease, leading to end-stage renal disease (ESRD) and death, both 
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in the developed and developing countries, as well. Of note, 
the excess risk of death from any cause among patients with 
diabetes is mainly associated with the presence of kidney 
disease. In the absence of diabetic nephropathy, the risk of 
death among persons with diabetes type 1 or type 2 is similar 
to that in the general population.1,2 The main alterations 
that occur in the initiation of diabetic nephropathy (DN) are 
increase of mesangial matrix, thickening of glomerular base-
ment membrane, hyperfiltration and increase of Glomerular 
Filtration Rate (GFR).1,2
P A t h o g E n E s I s  o f  d I A b E t I c  K I d n E y 
d I s E A s E
These alterations are related to changes such as increased 
production of adipocytokines and reactive oxygen species 
along with accumulation of advanced glycation end products 
(AGEs), which lead to deposition of mesangial matrix, glomer-
ular sclerosis, and tubulointerstitial fibrosis. In this complex 
process growth factors, such as TGF-β (Transforming Growth 
Factor-β) and VEGF (Vascular Endothelial Growth Factor) 
along with proinflammatory cytokines, such as IL-1, IL-6 and 
TNF-a play a key-role. Also, oxidative stress is implicated in 
the mesangial cell proliferation and podocytopathy, which 
leads to mesangial expansion and glomerular basal membrane 
thickening.3,4
On the other hand, hemodynamic changes result in hyper-
filtration, an early event in the course of type 2 diabetes, which 
usually precedes the diagnosis of diabetes.5,6 Hyperfiltration 
is documented to be followed by a progressive decrease in 
glomerular filtration rate (GFR). Specifically, hyperfiltration 
leads to early glomerular death. In diabetes mellitus, glo-
merular hyperfiltration is suggested to be due to glomerular 
hemodynamic changes as well as glomerular-tubular feedback 
mechanisms.5,6
Hyperglycemia-induced dysregulation of the glomerular 
afferent and efferent arteriole tone, which leads to higher 
decrease in the afferent arteriolar tone compared with the 
efferent arteriolar tone is mostly driven by local upregulation 
of angiotensin II. The hemodynamic mechanism behind this 
dysregulation is complex, but it is noteworthy that the efferent 
glomerular arteriole is 10 – 100 times more sensitive to the 
vasoconstrictive properties of angiotensin II than the afferent 
arteriole, and this might account for the consequent higher 
intraglomerular capillary pressure, which is believed to be the 
cornerstone of diabetic nephropathy.7
In normal subjects, the tubuloglomerular feedback au-
toregulates glomerular filtration by changing the tone of the 
afferent glomerular arteriole. In particular, an enhancement in 
distal sodium concentrations results in increased vasoconstric-
tion of the afferent glomerular arteriole by the macula densa, 
while a decrease in sodium concentrations in the distal tubuli, 
leads to vasodilation of the afferent glomerular arteriole. In 
patients with type 2 diabetes mellitus, upregulation of glucose 
and sodium reabsorption by sodium glucose co-transporter 2 
(SGLT-2) in the S1 and S2 segments of the proximal tubule, 
accounts for a local decrease in sodium levels and subsequent 
vasodilation of the afferent glomerular arteriole thereby result-
ing in enhanced filtration.8,9
t r E A t m E n t  o P t I o n s  f o r  d I A b E t I c 
K I d n E y  d I s E A s E
The management of diabetic nephropathy focuses on 
the treatment of hyperglycemia and hypertension, with the 
inhibition of the renin-angiotensin-aldosterone system being 
the cornerstone of treatment.10 Regarding hyperglycemia, 
intensifying the management of glycemia to lower glycated 
hemoglobin targets in older people with type 2 diabetes 
(ie. glycated hemoglobin, <6.0 to 6.5% in persons typically 
>60 years of age, depending on the study) has been shown 
to produce small decreases in the risk of albuminuria onset 
or progression, but has been associated with more frequent 
episodes of severe hypoglycemia than conventional glycemic 
management. Moreover, these targets have not reduced the 
risk of death, cardiovascular disease, or ESRD.10 Therefore, 
glycated hemoglobin at the levels of <7% should be aimed as 
usually recommended.10
Regarding hypertension, drugs inhibiting the renin-
angiotensin-aldosterone system remain the gold standard of 
treatment, as they have been documented to reduce urinary 
albumin excretion rates and thereby mitigating progression to 
ESRD.11 Angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs) reduce intra-glomerular 
pressure by inhibiting angiotensin II mediated efferent arteri-
olar vasoconstriction. Thus, apart from their anti-hypertensive 
properties they possess anti-proteinuric potential, too. Urine 
albumin at concentrations >30 mg/g creatinine (ACR) is a 
strong predictor of cardiovascular adverse events. Therefore, 
annually determination of ACR together with serum creatinine 
levels and calculation of GFR using the CKD-EPI calculator 
is mandatory. Whether the goal of treatment of systolic blood 
pressure <140 mmHg -which is still our aiming- will prove to 
be efficacious among patients with diabetes and nephropathy 
remains to be elucidated. Another disappointing feature has 
been maximal inhibition of the renin- angiotensin-aldosterone 
system. Dual-blockade strategies (an angiotensin-converting-
enzyme inhibitor plus an angiotensin-receptor blocker or one 
of those agents plus a renin inhibitor) have lowered the risk 
of albuminuria, but have increased the risk of adverse events 
(hyperkalemia, hypotension and acute kidney injury), without 
reducing the risk of ESRD.12-14 Apart from the inhibition of the 
renin-angiotensin-aldosterone system, other antihypertensive 
drugs that seem to reduce albuminuria are dihydropyridine 
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calcium antagonists, such as manidipine, non-dihydropyridine 
calcium antagonists, such as diltiazem and verapamil, as well 
as newer b-blockers, such as carvedilol.15,16
Furthermore, fighting hyperlipidemia with hypolipidemic 
agents, such as statins and/or ezetimibe or the newer category 
of PCSK9 inhibitors seems to be fundamental, too.17 It seems 
likely that dyslipidemia is involved in oxidative stress and the 
production of proinflammatory cytokines, as has been men-
tioned above.3,4,18
Patients with chronic kidney disease have a very high 
prevalence of deficiency of 25-hydroxyvitamin D. Although the 
endocrine effects of vitamin D are widely recognized, some-
what less appreciated is that vitamin D may possess paracrine 
functions through local activation by 1-α-hydroxylase and thus 
maintain immunity, vascular function, cardiomyocyte health, 
and diminish inflammation and insulin resistance. In the kid-
ney, vitamin D may be important for maintaining podocyte 
health, preventing epithelial-to-mesenchymal transformation, 
and suppressing renin gene expression and inflammation. Re-
placement with pharmacologic dosages of vitamin D analogues 
in animal models of kidney disease have consistently shown 
reductions in albuminuria and minimization of glomeruloscle-
rosis and glomerular inflammation. Emerging evidence in pa-
tients with chronic kidney disease has documented that vitamin 
D can reduce proteinuria or albuminuria even in the presence 
of angiotensin-converting enzyme inhibition. In addition to 
reducing proteinuria, Vitamin D analogues may reduce insulin 
resistance, blood pressure and inflammation and may preserve 
podocyte loss; thus, providing biologic plausibility to the no-
tion that the use of these agents may exert favorable outcomes 
in patients with diabetic nephropathy. Moreover, vitamin D 
analogues have been shown to decrease albuminuria, probably 
through i) inhibition of the renin-angiotensin-aldosterone 
system ii) immune and anti-inflammatory potential and iii) 
inhibition of mesangial fibrosis by affecting FGF-23 (Fibro-
blast Growth Factor-23) in the diabetic kidney. In particular, 
in a study enrolling >100.000 participants a six-fold incidence 
of hypertension has been recorded among participants with 
serum 25(OH)D levels <15 ng/ml, in comparison with those 
that have had serum 25(OH)D levels ≥30 ng/ml.19-20
In the EMPA-REG Study (Empagliflozin Cardiovascular 
Outcome Event Trial) among 7,928 type 2 diabetic patients 
with increased cardiovascular risk, the relative risk of serum 
creatinine doubling has been reduced by 44%, while the 
relative risk of starting hemoperfusion has been reduced by 
55% at four years of monitoring those patients.21 This study 
has introduced the SGLT-2 Inhibitors (Sodium Glucose Co-
transporters 2 Inhibitors) at the heart of the management of 
type 2 diabetes not only because of their cardioprotective prop-
erties, but due to their nephroprotective potential, as well.22
Among dipeptidyl-dipeptidase-4 inhibitors, linagliptin 
has been documented to lower albuminuria on top of recom-
mended standard treatment in patients with type 2 diabetes and 
renal dysfunction.23 Regarding patients with type 2 diabetes, 
linagliptin has been shown to ameliorate albuminuria, probably 
by means of combating oxidative stress as well as by interfer-
ing with the formation of advanced glycation end products.23
As endothelin plays a pivotal role in vasocontriction and 
thus is involved in increasing the intraglomerular pressure, 
it seems likely that endothelin inhibition could prevent the 
progression of diabetic nephropathy. Atrasentan is a highly 
specific inhibitor of endothelin A receptors in the kidney. It has 
been shown to reduce albuminuria by 35% among 211 patients 
with type 2 diabetes. Also, a decrease in systolic and diastolic 
blood pressure as well as LDL-cholesterol and triglycerides 
has been documented after the administration of atrasentan. 
Fluid retention and anemia are the most common adverse ef-
fects that have been associated with atrasentan, but have been 
mitigated with the withdrawal of this agent.24 
Last but not least, are the dietary habits that diabetic 
patients have to follow, in order to fight the obesity epidemic 
that keeps rising. GFR has been documented to decrease after 
tAblE 1. Agents that have established efficacy in prevent-
ing diabetic nephropathy, novel therapeutic interventions and 
agents under investigation. (NAC: N-acetyl-cysteine; XO inhibi-
tors: Xanthino-oxidase inhibitors; DPP-4 inhibitors: dipeptyl-
peptidase-4 inhibitors; ET: Endothelin; VDR activators: Vita-
min D Receptor activators; MRA: Mineralocorticoid receptor 
antagonists; RAS: Renin-angiotensin system; ACEI: Angioten-
sin convertor enzyme inhibitors; ARB: Angiotensin II receptor 
blockers). 
Established Factors
RAAS Blockade; ACE; ARB
Blood Pressure Control
Glycemic Control
Novel Factors
DPP-4 Inhibitors
SGLT-2 Inhibitors
Selective ER Receptor Antagonists
VDR Activators
MRA
Investigational Factors
Antioxidants: NAC, pentoxyfylline, etc
XO Inhibitors
Antifibrotic Agents
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body weight loss among patients with obesity.25 Obesity is re-
lated to ESRD, in part due to its relationship to diabetes and 
hypertension. However, obesity per se seems to be associated 
with a 1.2 to 1.6 increase in relative risk for chronic kidney 
disease. Therefore, weight loss of even 5 kilos is fundamental 
in preventing diabetic nephropathy. Referral to dieticians who 
are involved in diets regarding diabetes is essential for the 
management of the diabetic patient. Also, among patients with 
diabetic nephropathy a diet including 0.8 protein/Kgr seems 
to be a prudent diet for the prevention of malnutrition, which 
is another problem of ESRD.25
c o n c l u s I o n
In order to minimize the risk of diabetic nephropathy 
among patients with type 1 or type 2 diabetes, combating hy-
perglycemia, hypertension, dyslipidemia and obesity all play 
a pivotal role. Among type 2 diabetic patients, the newer class 
of SGLT-2 Inhibitors together with the dipeptidyl-dipeptidase 
inhibitor-4 linagliptin seem to be very promising. Furthermore, 
vitamin D analogues together with agents that possess anti-
oxidant and anti-inflammatory properties, such as allopurinol, 
febuxostat, MCP-1, pentoxyphylline and N-acetyl-cysteine are 
still under investigation (Fig. 1). Further research is warranted 
in order to decrease the rates of diabetic nephropathy, which 
keep rising together with the diabetes epidemic. 
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